osimertinib
astrazeneca
['elios']
terrific presentation by of at . elios trial highlights that even in a prospective study with planned post-pd tissue biopsies to id mechanisms of res to egfr tkis, only 39% ultimately have sufficient material for ngs. 
Director, Center for Thoracic Cancers; Director, Targeted Immunotherapy; Thoracic Oncologist, Mass General Hospital, Harvard Medical School. Views my own.